Bora Pharmaceuticals, a contract development and manufacturing organization (CDMO) that specializes in complex modified release (MR) products and solvent production, has announced the opening of its first North American office in Delaware.
 
The Asia-Pacific (APAC)-headquartered CDMO, which has invested over $60 million in acquiring world class facilities in recent years, has established the office as part of its two-year plan to invest in the North American market.
 
“Opening an office on the East coast of the U.S., is a significant milestone for our organization and signals our continued commitment to the region,” said Bobby Sheng, chief executive officer, Bora. “The office is one phase of our expansion plans, as we continue to explore acquisition opportunities in the market. It will not only support our own future growth strategy but also allows us to better support our growing client base, as companies across the U.S. continue to outsource their most complex oral solid dose (OSD) projects to Bora.”
 
Bora appointed its U.S. managing director of business development, Louis Weber, in late 2018 and he will lead the company’s growth strategy across North America and Europe.
 
Previously a senior director of business development at Halo Pharma (now acquired by Cambrex), Mr. Weber has almost 20 years’ experience in the pharmaceutical sector and sits at the forefront of Bora’s growth strategy.
 
Mr. Weber said, “As an industry, we are seeing a rising demand for large scale manufacturing projects that have the same diverse and challenging requirements of niche drug products. This is what attracted me to Bora, as its sweet spot is providing complex dosage forms on a large commercial scale.
 
Bora offers a broad range of technologies across its multiple sites, from small scale R&D capabilities to large scale manufacturing services. The company also provides packaging, distribution, tech transfer, stability studies, and product life cycle management capabilities for clinical trial and commercial projects.
 
The publicly listed company is one of the largest CDMOs in Asia. This announcement follows the recent reports of Bora’s fifth successful FDA inspection with zero 483 observations at its export manufacturing facility in Zhunan, Taiwan.
 
Bora will be exhibiting at CPhI Worldwide alongside the Taiwan Pharmaceutical Alliance. Visit stand 80B50.